Inclusion Criteria

INCLUSION CRITERIA:

Patient must understand and sign the informed consent.

Patient must be at least 18 years of age.

Patient must have retinal angiomas secondary to VHL in one or both eyes.

Patient must have either optic nerve tumors or peripheral tumors that have caused central
vision loss of 20/40 or worse.

Patient must have clear ocular media and adequate papillary dilation to permit good
quality stereoscopic fundus photography.

Patients must be post menopausal, surgically sterile for at least 12 months prior to study
entry, or agree to use at least two effective forms of birth control.

All women of childbearing potential must have a negative serum pregnancy test at baseline
and immediately prior to each injection and for at least 60 days following the last dose
of EYE001.

Patient must have lab values indicative of adequate hematological function (hemoglobin
greater than or equal to 10 g/dl, platelet count less than or equal to 130 x 10(9)/I, WBC
3.8-10.8 x 10(9)/I) within one month of baseline.

Patients must have lab values indicative of adequate liver function (serum bilirubin less
than or equal to 1.5 mg/dl, SGOT/ALT, SGPT/AST, GGT and alkaline phosphotase within 2 x
ULN) within one month of baseline.

Patients must have lab values indicative of adequate renal function serum creatinine less
than or equal to 2.0 mg/dl and BUN within 2.0 x ULN within one month of baseline.

EXCLUSION CRITERIA:

Significant media opacities, including cataract that precludes quality fundus photographs
of the posterior pole.

History or evidence of severe cardiac disease (electrocardiogram abnormalities, clinical
history of unstable angina, acute coronary syndrome, myocardial infarction,
revascularization procedure within 6 months prior to baseline, atrial or ventricular
tachyarrythmias requiring ongoing treatment).

History of stroke within 12 months of study entry.

History of or current acute ocular or periocular infection (including any history of
ocular herpes zoster).

Any major surgical procedure within one month of study entry.

Known serious allergies to fluorescein dye.